Company intelligence

ELVN

Enliven Therapeutics, Inc. · NASDAQ · Healthcare

Price$54.32-3.40% · −$1.91

Market cap3.88BEquity value

P / E-32.5Trailing ratio

Volume995.81KLatest session

Market data

ELVN price chart

TradingView

Related signals

1 min delayed

Browse public ELVN signals with their source context and measured market impact. Open any signal for its permanent analysis page.

ELVNAug 18, 2026-0.08% since signal

William Blair Initiates Coverage on ELVN, Sees ELVN-001 as CML Disruptor

William Blair initiated coverage on Enliven Therapeutics with an Outperform rating, highlighting ELVN-001's potential to reshape CML therapy. The catalyst is the coverage stance and potential progress updates, though no trial data were disclosed. If ELVN-001 delivers positive data or milestones, ELVN could see near-term re-rating.

View signal analysis

ELVNJan 8, 2026+11.69% since signal

Enliven Therapeutics Early Leukemia Drug Results Impress, Stock Soars

ELVN shares surge 50.42%, trading at $23.27. Phase 1b ENABLE trial shows strong efficacy for ELVN-001 in CML. 38% MMR and 16% DMR rates in 80 mg cohort; 53% MMR in 60 mg cohort. No new safety signals observed; favorable safety profile maintained. Phase 3 ENABLE-2 trial set to begin in second half of 2026.

View signal analysis

Research